Rapport Therapeutics Q2 2026: Cash Runway Extended to H2 2029, Phase 3 FOS Trial Underway
RAPP has more than doubled off its 52-week low of $13.62.
Summary
Rapport Therapeutics' Q2 2026 10-Q shows a $56.6M net loss, $436.1M in cash extending runway to H2 2029, and the launch of Phase 3 trials for its lead epilepsy drug. Phase 2 bipolar mania data is expected in October 2026.
Key Events · Earnings and Guidance · RAPP
-
Cash Runway Extended to H2 2029
Cash, cash equivalents and short-term investments totaled $436.1 million as of June 30, 2026, funding operations into the second half of 2029.
-
Phase 3 FOS Trial Initiated
The Phase 3 program for RAP-219 in drug-resistant focal onset seizures began in Q2 2026, following positive Phase 2a data and FDA feedback.
-
Phase 2 Bipolar Mania Data in October 2026
Topline results from the Phase 2 proof-of-concept trial of RAP-219 in bipolar mania are expected in October 2026, with the trial potentially serving as confirmatory evidence.
-
RAP-219 Half-Life Updated to 22 Days
Pharmacokinetic modeling now estimates a 22-day half-life for RAP-219, up from 14 days, supporting sustained receptor occupancy and durable clinical responses.
Analysis · RAPP · Life Sciences
A net loss of $56.6 million marked Rapport Therapeutics' second quarter of 2026, fueled by a sharp rise in R&D spending as the company launched its Phase 3 program for RAP-219 in drug-resistant focal onset seizures. Closing the quarter with $436.1 million in cash and investments extends the runway into the second half of 2029 — a critical buffer for a pre-revenue biotech advancing multiple late-stage trials. The Phase 2 bipolar mania trial remains on track for topline data in October 2026, a near-term catalyst. The filing also disclosed an updated 22-day half-life for RAP-219, supporting sustained efficacy, and an amended director compensation policy. While the loss widened year-over-year, the strong cash position and clinical execution reinforce the investment thesis.
At the time of this filing, RAPP was trading at $40.51 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2B. The 52-week trading range was $13.62 to $44.28. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.